(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 22.8% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.27%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.04%.
Grail's revenue in 2026 is $156,120,000.On average, 11 Wall Street analysts forecast GRAL's revenue for 2026 to be $7,841,719,873, with the lowest GRAL revenue forecast at $7,234,020,916, and the highest GRAL revenue forecast at $8,426,673,036. On average, 11 Wall Street analysts forecast GRAL's revenue for 2027 to be $9,791,420,693, with the lowest GRAL revenue forecast at $8,613,360,215, and the highest GRAL revenue forecast at $11,274,618,147.
In 2028, GRAL is forecast to generate $12,539,370,143 in revenue, with the lowest revenue forecast at $9,967,807,890 and the highest revenue forecast at $15,780,860,412.